What Research and Treatment Progress Is Underway for HHT?

HHT research is moving on two fronts at once: a treatment pipeline that currently includes 15 therapies, and a care network of more than 55 HHT Centers of Excellence worldwide that turns those findings into practice. Cure HHT, which has served the HHT community since 1991, describes its goal as a future where HHT is found sooner, treated better, and ultimately cured. If you are trying to understand where the science stands, the most useful frame is not a single breakthrough but the combination of pipeline activity, clinical infrastructure, and earlier diagnosis.

The current treatment pipeline

According to Cure HHT, there are 15 treatments in the HHT pipeline today. For context, 3 treatments entered the pipeline between 2018 and 2022. That comparison matters: it suggests the pace of therapeutic development has picked up rather than stayed flat.

A few things worth knowing about what a "pipeline" number does and does not tell you:

• It counts therapies under development or investigation, not treatments already approved and available to every patient.
• A pipeline entry can stall, change purpose, or fail before it reaches routine care.
• The number is a snapshot, so it will shift over time.

What it does tell you is that HHT is an active research target, not a neglected disease.

Why research alone isn't the whole story

Cure HHT frames its work as bringing patients, families, clinicians, researchers, and partners together around one shared goal. That coordination is the mechanism behind the numbers:

• Expert care — 55+ HHT Centers of Excellence worldwide give patients access to specialists who see HHT regularly rather than rarely.
• Clinical guidance — guideline-based screening and management tools help clinicians across specialties recognize and handle HHT consistently.
• A growing research community — researchers connected to the same network are more likely to enroll patients, share data, and test ideas.
• New paths toward treatment — the pipeline above is the visible output of that network.

For a patient, this means the practical route to better care usually runs through a Center of Excellence, not through waiting for a new drug. Screening, monitoring, and management are available now.

The diagnosis gap driving the research agenda

Cure HHT's stated priorities — found sooner, treated better, cured — map directly onto a striking set of figures:

The 80% undiagnosed figure explains why "found sooner" leads the agenda. HHT often begins with nosebleeds in childhood, but Cure HHT stresses that it is a whole-body disease — malformed blood vessels can affect multiple organs, and some of the most serious complications can exist without obvious symptoms. Research into earlier detection therefore has a direct effect on outcomes, independent of any new therapy.

What this means if you are newly diagnosed

The research picture is encouraging, but it does not change what you should do first. A diagnosis is a starting point: find out what to screen for, build a care plan, and consider what your family may need to know. Because HHT is genetic and frequently undiagnosed, family screening is often part of the conversation.

If you are looking for care, the most direct step is to find an HHT Center of Excellence or an HHT-experienced physician near you. If you are a clinician, Cure HHT offers guideline-based screening and management guidance, clinical tools, and referral pathways.

How to follow progress without overreading it

If you want to track HHT research as it develops, keep three distinctions in mind:

1. Pipeline vs. approved — a therapy in development is not yet a treatment option.
2. Numbers vs. timing — a count of 15 tells you activity, not when anything reaches patients.
3. Research vs. care — better screening and specialist care help patients today, regardless of pipeline timing.

Cure HHT invites patients, families, and professionals to join its community for research breakthroughs, patient stories, and webinar invitations. For anyone affected by HHT, that is a reasonable way to stay current while relying on established care in the meantime.